1. Overexpression of cMOAT (MRP2/ABCC2) Is Associated with Decreased Formation of Platinum-DNA Adducts and Decreased G2-Arrest in Melanoma Cells Resistant to Cisplatin 
Bernd Liedert, Verena Materna, Dirk Schadendorf, Jürgen Thomale, Hermann Lage 
Journal of Investigative Dermatology 
Volume 121, Issue 1, Pages (July 2003)
DOI: /j x
Copyright © 2003 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
(A) Northern blot analysis of cMOAT mRNA expression in human melanoma cells. RNA was hybridized with a 32P-labeled cMOAT-specific cDNA. As control, the blots were probed with a cDNA probe of GAPDH. (B) Relative cMOAT mRNA expression level after normalization against GAPDH expression level determined by quantitative real time reverse transcription–PCR using a LightCycler instrument. Cisplatin-resistant MeWo CIS 1 cells showed a 3.7-fold enhanced expression of the cMOAT mRNA. (C) Western blot analysis using a mouse MoAb M2I-4 directed against cMOAT. As control, a mouse MoAb directed against actin was used.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 2003 The Society for Investigative Dermatology, Inc Terms and Conditions

3. Figure 2
Cell cycle analyses of drug-sensitive (MeWo) and cisplatin-resistant (MeWo CIS 1) melanoma cells after propidium iodide staining using flow cytometry. Analyses were performed at 0 h, 24 h, 48 h, and 72 h after cisplatin treatment. (A) Exposure of MeWo to 5 μg cisplatin per mL: t=0 h, 31.4% in S+G2 phase; t=24 h after cisplatin treatment, 80.0% in S+G2 phase; t=48 h after cisplatin treatment, 67.2% in S+G2 phase; t=72 h after cisplatin treatment, 56.1% in S+G2 phase. (B) Exposure of MeWo CIS 1–5 μg cisplatin per mL: t=0 h, 30.9% in S+G2 phase; t=24 h after cisplatin treatment, 58.3% in S+G2 phase; t=48 h after cisplatin treatment, 40.5% in S+G2 phase; t=72 h after cisplatin treatment, 29.6% in S+G2 phase. (C) Exposure of MeWo to 20 μg cisplatin per mL: t=0 h, 31,4% in S+G2 phase; t=24 h after cisplatin treatment, 87,4% in S+G2 phase; t=48 h after cisplatin treatment, 92.2% in S+G2 phase; t=72 h after cisplatin treatment, 98,7% in S+G2 phase. (D) Exposure of MeWo CIS 1–20 μg cisplatin per mL: t=0 h, 30,9% in S+G2 phase; t=24 h after cisplatin treatment, 79.2% in S+G2 phase; t=48 h after cisplatin treatment, 66,6% in S+G2 phase; t=72 h after cisplatin treatment, 63.7% in S+G2 phase.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 2003 The Society for Investigative Dermatology, Inc Terms and Conditions

4. Figure 3
Time kinetics of cisplatin-induced Pt-d(GpG) adduct formation in the drug-sensitive melanoma line MeWo and its cisplatin-resistant subline MeWo CIS 1 as measured by an immunocytologic assay. Cisplatin was added at t=– 2 h. The cells were exposed to 5 or 20 μg per mL cisplatin for 2 h and nuclear Pt-d(GpG) adduct content was determined after different time periods by fluorescence microscopy using the rat anti-Pt-d(GpG) adduct MoAb “18G10” and a fluorescein isothiocyanate-based double sandwich staining procedure. Signals were amplified and recorded by a dual mode CCD camera, and fed into a four parameter image analysis program. Displayed values represent the mean, the vertical error bars SD.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 2003 The Society for Investigative Dermatology, Inc Terms and Conditions